Literature DB >> 33681693

Recommendations from a Dialogue on Evolving National Cancer Institute-Designated Comprehensive Cancer Center Community Outreach and Engagement Requirements: A Path Forward.

Patricia M Doykos1, Moon S Chen2, Karriem Watson3, Vida Henderson3, Monica L Baskin4, Sarah Downer5, Lauren A Smith6, Neeraja Bhavaraju6, Samantha Dina6, Christopher S Lathan7.   

Abstract

While cancer mortality is declining in the United States, significant racial, ethnic, economic and geographic inequities persist. To help address inequities in cancer treatment, care, support and research, the National Cancer Institute (NCI) instituted the community outreach and engagement (COE) mandate for NCI-designated comprehensive cancer centers (CCCs). The Bristol Myers Squibb Foundation designed a convening and listening session on COE with NCI leaders and staff gathering representatives from CCCs and the broader cancer community. This paper captures recommendations from the listening session for the NCI and CCCs to further evolve the implementation and impact of the COE mandate on cancer control and outcomes. © Patricia M. Doykos et al., 2021; Published by Mary Ann Liebert, Inc.

Entities:  

Keywords:  cancer center; cancer institute; community outreach and engagement

Year:  2021        PMID: 33681693      PMCID: PMC7929918          DOI: 10.1089/heq.2020.0156

Source DB:  PubMed          Journal:  Health Equity        ISSN: 2473-1242


  2 in total

1.  A National Map of NCI-Designated Cancer Center Catchment Areas on the 50th Anniversary of the Cancer Centers Program.

Authors:  Peter F DelNero; Ian D Buller; Rena R Jones; Zaria Tatalovich; Robin C Vanderpool; Henry P Ciolino; Robert T Croyle
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2022-05-04       Impact factor: 4.090

2.  Assessing the Coverage of US Cancer Center Primary Catchment Areas.

Authors:  Amy E Leader; Christopher McNair; Christina Yurick; Matthew Huesser; Elizabeth Schade; Emily E Stimmel; Caryn Lerman; Karen E Knudsen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2022-05-04       Impact factor: 4.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.